跳至主要内容
临床试验/NL-OMON40637
NL-OMON40637已完成不适用

An open-label, multiple-dose, sequential, 2 treatment period study to evaluate the effect of QBW251 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in pre-menopausal healthy female volunteers - CQBW251X22102 (CS0216)

ovartis0 个研究点目标入组 47 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
ovartis
入组人数
47

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Healthy premenopausal female subjects age 18 to 50 years of age. Stable regimen of monophasic OC containing EE (30 µg)/LVG (150 µg) for at least three cycles prior to dosing in treatment period.;Any Subject not taking any OC or taking another brand of;monophasic OC (which does not contain 30 µg EE and 150 µg LVG);should be willing to take a monophasic OC containing 30 µg EE and;150 µg LVG for at least three cycles during synchronization until day -7.;Negative pregnancy test results at screening and both baseline;visits.

排除标准

  • Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations.;Women of child-bearing potential, defined as all women;physiologically capable of becoming pregnant, unless they are using contraception methods.;Women who are either heterozygous or homozygous for the Factor V Leiden mutation.

研究者

发起方
ovartis

相似试验